US FDA grants accelerated approval to Genfit and Ipsen's liver disease drug
Adds details on pricing in paragraph 3, background throughout
By Puyaan Singh and Mariam Sunny
June 10 (Reuters) -The U.S. Food and Drug Administration granted accelerated approval toFrench drugmakers Ipsen IPN.PA and Genfit's GNFT.PA drug for achronic inflammatory liver disease, Iqirvo, the companies saidon Monday.
Primary biliary cholangitis (PBC) causes inflammation of the small bile ducts in the liver and eventually destroys them. It primarily affects women aged 30 to 60, impacting 75,000 in the United States.
Iqirvo's estimated price is $11,500 for a month's supply, and it is already available for healthcare providers to prescribe in the U.S., Ipsen said.
Ipsen added that standard approval for Iqirvo may be contingent on confirmatory trials, as improvement in survival or prevention of liver decompensation events that can include abdominal swelling or gastrointestinal bleeding was not demonstrated.
Intercept Pharmaceuticals' ICPT.MX Ocaliva is approved for PBC patients in combination with ursodeoxycholic acid (UDCA), or as a monotherapy inpatients unable to tolerate UDCA. Iqirvo is also to be used under similar conditions, based on this approval.
Iqirvo's approval was based on data from a 161-patient late-stage trial, in which it reduced levels of an enzyme called alkaline phosphatase that can lead to liver damage.
It works by activating certain receptors, which reduce inflammation, increases transport of bile acids outside the liver and promotes their detoxification, said Christelle Huguet, Executive Vice President at Ipsen.
Current treatments do not address inflammation or scarring of the liver and do not promote detoxification of bile acids, Huguet added.
In the study, Iqirvo alsoshowed an improvement in itchy skin - a symptom of PBC - over placebo. Othertreatments such as Ocaliva can worsen itching.
Ipsen acquired global rights to license the drug from Genfit in 2021. Genfit received 120 million euros ($129.19 million) upfront and is eligible to receive double-digit royalties of up to 20%.
Gilead GILD.O is also developing a drug for PBC, on which the FDA is expected to decide in August.
($1 = 0.9289 euros)
Reporting by Puyaan Singh and Mariam Sunny in Bengaluru; Editing by Krishna Chandra Eluri and Alan Barona
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
